CN104364655A - 贝伐单抗组合疗法用于治疗乳腺癌的血浆生物标志物 - Google Patents

贝伐单抗组合疗法用于治疗乳腺癌的血浆生物标志物 Download PDF

Info

Publication number
CN104364655A
CN104364655A CN201380030336.6A CN201380030336A CN104364655A CN 104364655 A CN104364655 A CN 104364655A CN 201380030336 A CN201380030336 A CN 201380030336A CN 104364655 A CN104364655 A CN 104364655A
Authority
CN
China
Prior art keywords
patient
expression
biomarker
vegf antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380030336.6A
Other languages
English (en)
Chinese (zh)
Inventor
U·克劳泽
N·穆尔
C·帕劳德
S·谢勒
N·怀尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN104364655A publication Critical patent/CN104364655A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380030336.6A 2012-06-26 2013-06-24 贝伐单抗组合疗法用于治疗乳腺癌的血浆生物标志物 Pending CN104364655A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261664612P 2012-06-26 2012-06-26
US61/664,612 2012-06-26
US201261697667P 2012-09-06 2012-09-06
US61/697,667 2012-09-06
PCT/EP2013/063094 WO2014001232A1 (en) 2012-06-26 2013-06-24 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Publications (1)

Publication Number Publication Date
CN104364655A true CN104364655A (zh) 2015-02-18

Family

ID=48672633

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380030336.6A Pending CN104364655A (zh) 2012-06-26 2013-06-24 贝伐单抗组合疗法用于治疗乳腺癌的血浆生物标志物

Country Status (10)

Country Link
EP (1) EP2864788A1 (ja)
JP (1) JP2015522815A (ja)
KR (1) KR20150024342A (ja)
CN (1) CN104364655A (ja)
BR (1) BR112014032456A2 (ja)
CA (1) CA2871385A1 (ja)
HK (1) HK1202334A1 (ja)
MX (1) MX2014014821A (ja)
RU (1) RU2015102026A (ja)
WO (1) WO2014001232A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018164518A1 (ko) * 2017-03-08 2018-09-13 한양대학교 산학협력단 Her2 양성 암 및 항-her2 치료에 대한 바이오마커 및 이의 용도
KR102028703B1 (ko) * 2017-11-21 2019-10-04 한양대학교 산학협력단 유방암의 진단 및 치료를 위한 바이오 마커

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910416A (zh) * 2007-11-09 2010-12-08 健泰科生物技术公司 在癌症患者中诊断性使用的方法和组合物
CN102099684A (zh) * 2008-02-29 2011-06-15 国立大学法人信州大学 前哨淋巴结内转移癌细胞检测试剂盒
WO2011088149A2 (en) * 2010-01-12 2011-07-21 Prometheus Laboratories Inc. Methods for predicting response of triple-negative breast cancer to therapy
CN102149828A (zh) * 2008-07-11 2011-08-10 霍夫曼-拉罗奇有限公司 用于肿瘤治疗的诊断用途的方法和组合物
CN102482715A (zh) * 2009-07-13 2012-05-30 霍夫曼-拉罗奇有限公司 用于癌症治疗的诊断方法和组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE97498T1 (de) 1984-01-30 1993-12-15 Imp Cancer Res Tech Verbesserungen an wachstumsfaktoren.
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5081034A (en) 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
WO1991005264A1 (en) 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE19806989A1 (de) 1998-02-19 1999-08-26 Roche Diagnostics Gmbh Erzeugung räumlich scharf begrenzter Festphasen für Bindungsassays
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
DE102004029909A1 (de) 2004-06-21 2006-01-19 Roche Diagnostics Gmbh Verfahren und Vorrichtung zur Herstellung von bindungsfähigen Reagenzträgern
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
KR20120059553A (ko) * 2009-08-14 2012-06-08 제넨테크, 인크. Ｖｅｇｆ 길항제에 대한 환자 반응을 모니터링하기 위한 생물학적 마커
JP2013537522A (ja) * 2010-07-19 2013-10-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌治療への応答可能性の増大した患者を同定する方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910416A (zh) * 2007-11-09 2010-12-08 健泰科生物技术公司 在癌症患者中诊断性使用的方法和组合物
CN102099684A (zh) * 2008-02-29 2011-06-15 国立大学法人信州大学 前哨淋巴结内转移癌细胞检测试剂盒
CN102149828A (zh) * 2008-07-11 2011-08-10 霍夫曼-拉罗奇有限公司 用于肿瘤治疗的诊断用途的方法和组合物
CN102482715A (zh) * 2009-07-13 2012-05-30 霍夫曼-拉罗奇有限公司 用于癌症治疗的诊断方法和组合物
WO2011088149A2 (en) * 2010-01-12 2011-07-21 Prometheus Laboratories Inc. Methods for predicting response of triple-negative breast cancer to therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADRIAN M JUBB, ADRIAN L HARRIS: "Biomarkers to predict the clinical effi cacy of bevacizumab in cancer", 《LANCET ONCOL》 *
BHUVANESVARI RAMASWAMY等: "Phase II Trial of Bevacizumab in CombinationwithWeekly Docetaxel inMetastatic Breast Cancer Patients", 《CLIN CANCER RES》 *

Also Published As

Publication number Publication date
BR112014032456A2 (pt) 2017-06-27
WO2014001232A1 (en) 2014-01-03
JP2015522815A (ja) 2015-08-06
CA2871385A1 (en) 2014-01-03
HK1202334A1 (en) 2015-09-25
KR20150024342A (ko) 2015-03-06
MX2014014821A (es) 2015-02-12
EP2864788A1 (en) 2015-04-29
RU2015102026A (ru) 2016-08-10

Similar Documents

Publication Publication Date Title
CN104067128A (zh) 贝伐单抗组合疗法用于治疗乳腺癌的血浆生物标志物
JP6057718B2 (ja) ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー
EP2596363B1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
AU2011281700B2 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
CN104364655A (zh) 贝伐单抗组合疗法用于治疗乳腺癌的血浆生物标志物
US20150352204A1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
AU2014208271B2 (en) Tumor tissue based biomarkers for bevacizumab combination therapies
AU2016247169A1 (en) Tumor tissue based biomarkers for bevacizumab combination therapies
Socinski Highlights in NSCLC From the 2012 American Society of Clinical Oncology Annual Meeting
NZ624444B2 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1202334

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150218

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1202334

Country of ref document: HK